3 01/10/2023 30/09/2024 2024-09-30 false false false false false false false true false false true false false false false false true false No description of principal activities is disclosed 2023-10-01 Sage Accounts Production 24.0 - FRS102_2024 xbrli:pure xbrli:shares iso4217:GBP 12869152 2023-10-01 2024-09-30 12869152 2024-09-30 12869152 2023-09-30 12869152 2022-10-01 2023-09-30 12869152 2023-09-30 12869152 2022-09-30 12869152 core:LandBuildings core:ShortLeaseholdAssets 2023-10-01 2024-09-30 12869152 core:PlantMachinery 2023-10-01 2024-09-30 12869152 core:NetGoodwill 2023-10-01 2024-09-30 12869152 bus:RegisteredOffice 2023-10-01 2024-09-30 12869152 bus:OrdinaryShareClass1 2023-10-01 2024-09-30 12869152 bus:OrdinaryShareClass2 2023-10-01 2024-09-30 12869152 bus:LeadAgentIfApplicable 2023-10-01 2024-09-30 12869152 bus:Director1 2023-10-01 2024-09-30 12869152 bus:Director2 2023-10-01 2024-09-30 12869152 bus:Director3 2023-10-01 2024-09-30 12869152 core:NetGoodwill 2023-09-30 12869152 core:NetGoodwill 2024-09-30 12869152 core:LandBuildings core:ShortLeaseholdAssets 2023-09-30 12869152 core:PlantMachinery 2023-09-30 12869152 core:LandBuildings core:ShortLeaseholdAssets 2024-09-30 12869152 core:PlantMachinery 2024-09-30 12869152 core:WithinOneYear 2024-09-30 12869152 core:WithinOneYear 2023-09-30 12869152 core:AfterOneYear 2024-09-30 12869152 core:AfterOneYear 2023-09-30 12869152 core:ShareCapital 2024-09-30 12869152 core:ShareCapital 2023-09-30 12869152 core:RetainedEarningsAccumulatedLosses 2024-09-30 12869152 core:RetainedEarningsAccumulatedLosses 2023-09-30 12869152 bus:OrdinaryShareClass1 core:ShareCapital 2024-09-30 12869152 bus:OrdinaryShareClass1 core:ShareCapital 2023-09-30 12869152 bus:OrdinaryShareClass2 core:ShareCapital 2024-09-30 12869152 bus:OrdinaryShareClass2 core:ShareCapital 2023-09-30 12869152 core:NetGoodwill 2023-09-30 12869152 core:LandBuildings core:ShortLeaseholdAssets 2023-09-30 12869152 core:PlantMachinery 2023-09-30 12869152 bus:SmallEntities 2023-10-01 2024-09-30 12869152 bus:AuditExemptWithAccountantsReport 2023-10-01 2024-09-30 12869152 bus:SmallCompaniesRegimeForAccounts 2023-10-01 2024-09-30 12869152 bus:PrivateLimitedCompanyLtd 2023-10-01 2024-09-30 12869152 bus:FullAccounts 2023-10-01 2024-09-30
Company registration number: 12869152
Moon Women's Health Ltd
Unaudited filleted financial statements
30 September 2024
Moon Women's Health Ltd
Contents
Directors and other information
Accountants report
Statement of financial position
Notes to the financial statements
Moon Women's Health Ltd
Directors and other information
Directors Mr Gavin Richard Burt
Ms Anna Janina Stephanie Glowacka
Mr Daniel Barry Talbot
Company number 12869152
Registered office 79 Dartmouth Park Road
London
England
NW5 1SL
Accountants Refigure Accounting Solutions Ltd
47 Redlands Road
Hadley
Telford
TF1 5LW
Moon Women's Health Ltd
Report to the board of directors on the preparation of the
unaudited statutory financial statements of Moon Women's Health Ltd
Year ended 30 September 2024
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Moon Women's Health Ltd for the year ended 30 September 2024 which comprise the statement of financial position and related notes from the company's accounting records and from information and explanations you have given us.
As a practising member firm of the Association of Chartered Certified Accountants , we are subject to its ethical and other professional requirements which are detailed at http://www.accaglobal.com/en/member/ professional-standards/ rules-standards/acca-rulebook.html.
This report is made solely to the board of directors of Moon Women's Health Ltd, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the financial statements of Moon Women's Health Ltd and state those matters that we have agreed to state to the board of directors of Moon Women's Health Ltd as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at https://www.accaglobal.com/content/dam/ACCA_Global/Technical/fact/tf-163-jan-24.pdf. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Moon Women's Health Ltd and its board of directors as a body for our work or for this report.
It is your duty to ensure that Moon Women's Health Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Moon Women's Health Ltd. You consider that Moon Women's Health Ltd is exempt from the statutory audit requirement for the year.
We have not been instructed to carry out an audit or a review of the financial statements of Moon Women's Health Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.
Refigure Accounting Solutions Ltd
47 Redlands Road
Hadley
Telford
TF1 5LW
7 April 2025
Moon Women's Health Ltd
Statement of financial position
30 September 2024
2024 2023
Note £ £ £ £
Fixed assets
Intangible assets 5 2,016 2,352
Tangible assets 6 21,046 24,605
_______ _______
23,062 26,957
Current assets
Debtors 7 7,729 8,055
Cash at bank and in hand 2,946 1,991
_______ _______
10,675 10,046
Creditors: amounts falling due
within one year 8 ( 3,758) ( 2,780)
_______ _______
Net current assets 6,917 7,266
_______ _______
Total assets less current liabilities 29,979 34,223
Creditors: amounts falling due
after more than one year 9 ( 81,128) ( 77,135)
_______ _______
Net liabilities ( 51,149) ( 42,912)
_______ _______
Capital and reserves
Called up share capital 10 3 3
Profit and loss account ( 51,152) ( 42,915)
_______ _______
Shareholders deficit ( 51,149) ( 42,912)
_______ _______
For the year ending 30 September 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
These financial statements were approved by the board of directors and authorised for issue on 07 April 2025 , and are signed on behalf of the board by:
Ms Anna Janina Stephanie Glowacka
Director
Company registration number: 12869152
Moon Women's Health Ltd
Notes to the financial statements
Year ended 30 September 2024
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 79 Dartmouth Park Road, London, England, NW5 1SL.
2. Statement of compliance
These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Going concern
As at the balance sheet date, the financial statements show that the company has liabilities in excess of assets of £51,149 (2023: £42,912) as a result of losses made to date. The financial statements have been prepared on a going concern basis as the directors who are also a shareholder has confirmed that they will continue to support the company for foreseeable future and meet the excess liabilities if the company is unable to do so.
Turnover
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Goodwill
Goodwill arises on business acquisitions and represents the excess of the cost of the acquisition over the company's interest in the net amount of the identifiable assets, liabilities and contingent liabilities of the acquired business. Goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. It is amortised on a straight line basis over its useful life. Where a reliable estimate of the useful life of goodwill or intangible assets cannot be made, the life is presumed not to exceed ten years.
Intangible assets
Intangible fixed assets are included at cost less accumulated amortisation.
Amortisation
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:
If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.
Tangible assets
tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
Short leasehold property - 10 % straight line
Plant and machinery - 25 % straight line
If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.
Impairment
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 3 (2023: 3 ).
5. Intangible assets
Goodwill Total
£ £
Cost
At 1 October 2023 and 30 September 2024 3,360 3,360
_______ _______
Amortisation
At 1 October 2023 1,008 1,008
Charge for the year 336 336
_______ _______
At 30 September 2024 1,344 1,344
_______ _______
Carrying amount
At 30 September 2024 2,016 2,016
_______ _______
At 30 September 2023 2,352 2,352
_______ _______
6. Tangible assets
Short leasehold property Plant and machinery Total
£ £ £
Cost
At 1 October 2023 and 30 September 2024 32,354 1,297 33,651
_______ _______ _______
Depreciation
At 1 October 2023 8,264 782 9,046
Charge for the year 3,235 324 3,559
_______ _______ _______
At 30 September 2024 11,499 1,106 12,605
_______ _______ _______
Carrying amount
At 30 September 2024 20,855 191 21,046
_______ _______ _______
At 30 September 2023 24,090 515 24,605
_______ _______ _______
7. Debtors
2024 2023
£ £
Trade debtors 337 545
Other debtors 7,392 7,510
_______ _______
7,729 8,055
_______ _______
8. Creditors: amounts falling due within one year
2024 2023
£ £
Trade creditors 3,758 2,780
_______ _______
9. Creditors: amounts falling due after more than one year
2024 2023
£ £
Other creditors 81,128 77,135
_______ _______
10. Called up share capital
Issued, called up and fully paid
2024 2023
No £ No £
Ordinary shares class A shares of £ 0.01 each 100 1 100 1
Ordinary shares class B shares of £ 0.01 each 200 2 200 2
_______ _______ _______ _______
300 3 300 3
_______ _______ _______ _______
11. Directors advances, credits and guarantees
Included within creditors are amounts due to the directors of the company, of £81,128 (2023: £77,135).